Time From Imaging to Endovascular Reperfusion Predicts Outcome in Acute Stroke
Authors:
- Jenny P. TsaiJTJenny P. Tsai
- Michael MlynashMMMichael Mlynash
- Soren ChristensenSCSoren Christensen
- Stephanie KempSKStephanie Kemp
- Sun KimSKSun Kim
- Nishant K. MishraNMNishant K. Mishra
- Christian FederauCFChristian Federau
- Raul G. NogueiraRNRaul G. Nogueira
- Tudor G. JovinTJTudor G. Jovin
- Thomas G. DevlinTDThomas G. Devlin
- Naveed AkhtarNANaveed Akhtar
- Dileep R. YavagalDYDileep R. Yavagal
- 1 April 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (4) , 952-957
Abstract
Background and Purpose—: This study aims to describe the relationship between computed tomographic (CT) perfusion (CTP)-to-reperfusion time and clinical and radiological outcomes, in a cohort of patients who achieve successful reperfusion for acute ischemic stroke. Methods—: We included data from the CRISP (Computed Tomographic Perfusion to Predict Response in Ischemic Stroke Project) in which all patients underwent a baseline CTP scan before endovascular therapy. Patients were included if they had a mismatch on their baseline CTP scan and achieved successful endovascular reperfusion. Patients with mismatch were categorized into target mismatch and malignant mismatch profiles, according to the volume of their Tmax >10s lesion volume (target mismatch, 100 mL). We investigated the impact of CTP-to-reperfusion times on probability of achieving functional independence (modified Rankin Scale, 0–2) at day 90 and radiographic outcomes at day 5. Results—: Of 156 included patients, 108 (59%) had the target mismatch profile, and 48 (26%) had the malignant mismatch profile. In patients with the target mismatch profile, CTP-to-reperfusion time showed no association with functional independence ( P =0.84), whereas in patients with malignant mismatch profile, CTP-to-reperfusion time was strongly associated with lower probability of functional independence (odds ratio, 0.08; P =0.003). Compared with patients with target mismatch, those with the malignant mismatch profile had significantly more infarct growth (90 [49–166] versus 43 [18–81] mL; P =0.006) and larger final infarct volumes (110 [61–155] versus 48 [21–99] mL; P =0.001). Conclusions—: Compared with target mismatch patients, those with the malignant profile experience faster infarct growth and a steeper decline in the odds of functional independence, with longer delays between baseline imaging and reperfusion. However, this does not exclude the possibility of treatment benefit in patients with a malignant profile.Keywords
This publication has 11 references indexed in Scilit:
- Efficacy of Stent-Retriever Thrombectomy in Magnetic Resonance Imaging Versus Computed Tomographic Perfusion–Selected Patients in SWIFT PRIME Trial (Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke)Stroke, 2017
- Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysisJAMA, 2016
- A benchmarking tool to evaluate computer tomography perfusion infarct core predictions against a DWI standardJournal of Cerebral Blood Flow & Metabolism, 2016
- Analysis of Workflow and Time to Treatment on Thrombectomy Outcome in the Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE) Randomized, Controlled TrialCirculation, 2016
- Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trialsThe Lancet, 2016
- Time-Dependent Computed Tomographic Perfusion Thresholds for Patients With Acute Ischemic StrokeStroke, 2015
- Response to endovascular reperfusion is not time-dependent in patients with salvageable tissueNeurology, 2015
- The Growth Rate of Early DWI Lesions is Highly Variable and Associated with Penumbral Salvage and Clinical Outcomes following Endovascular ReperfusionInternational Journal of Stroke, 2015
- Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trialThe Lancet Neurology, 2014
- Refining the Definition of the Malignant ProfileStroke, 2011